Kopylov, U., Verstockt, B., Biedermann, L., Sebastian, S., Pugliese, D., Sonnenberg, E., Steinhagen, P. R., Arebi, N., Ron, Y., Kucharzik, T., Roblin, X., Ungar, B., Bar-Gil Shitrit, A., Ardizzone, S., Molander, P., Coletta, M., Peyrin-Biroulet, L., Bossuyt, P., Avni-Biron, I., Tsoukal, E. I., Allocca, M., Katsanos, K., Raine, T., Sipponen, T., Fiorino, G., Ben-Horin, S., Eliakim, R., Armuzzi, A., Siegmund, B., Baumgart, D. C., Kamperidis, N., Maharshak, N., Maaser, C., Mantzaris, G., Yanai, H., Christodoulou, D., Dotan, I., & Ferrante, M. (n.d.). dOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. Journal of Crohn's and colitis, 12, S029–S030. http://access.bl.uk/ark:/81055/vdc_100095513553.0x00000e